Clinical trials: NSCLC, Stage IIIA
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Trial name
- NCT03366766
- Testing
- Nivolumab, Cisplatin, Pemetrexed Disodium
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00408499
- Testing
- cetuximab, erlotinib
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Davis
Lung Cancer
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
RATIONALE: MET/VEGFR2 inhibitor Foretinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01068587
- Testing
- MET/VEGFR2 inhibitor Foretinib, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- 4 sites in Canada
- Volunteers
- 31 people
- Sponsor
- NCIC Clinical Trials Group
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating…
- Trial name
- NCT06693336
- Testing
- SMS001
- Where
- 2 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- ToLymph Inc.
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT05340309
- Testing
- Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Southern California
Lung Cancer
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells.
- Trial name
- NCT00589056
- Testing
- cisplatin, etoposide, nelfinavir mesylate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage IIIA/B
Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)
Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
- Trial name
- NCT02118415
- Testing
- Hsp70-peptide TKD/IL-2 activated, autologous NK cells
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Technical University of Munich
Lung Cancer
Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Treatment plus supportive care may improve quality of life in patients undergoing cancer treatment.
- Trial name
- NCT00022009
- Testing
- gemcitabine hydrochloride
- Where
- United Kingdom
- Sponsor
- The Christie NHS Foundation Trust
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
This phase I/Ib trial studies the side effects and best dose of pembrolizumab when given together with afatinib dimaleate in treating patients with non-small cell lung cancer that has spread to other places in the body and…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02364609
- Testing
- Afatinib Dimaleate, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonathan Riess
Colorectal Cancer, Lung Cancer
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
RATIONALE: A disease management program may be more effective than standard therapy in improving quality of life and controlling symptoms in patients with cancer.
- Conditions
- Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00684801
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 605 people
- Sponsor
- Case Comprehensive Cancer Center
Anorexia, Lung Non-Small Cell Carcinoma
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
This phase II/III trial studies how well anamorelin hydrochloride works in reducing anorexia in patients with non-small cell lung cancer that has spread to other places in the body.
- Conditions
- Anorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03637816
- Testing
- Anamorelin Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Study of Tumor Samples From Patients With Lung Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900328
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
This study is being done to compare a special type of Positron Emission Tomography (PET) scan with CT scan in patients with surgically removable lung cancer to see which method is more useful in measuring a response to treatment.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT00963807
- Testing
- Cisplatin, CT, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal…
- Trial name
- NCT00547105
- Testing
- Erlotinib, SBRT
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
NSCLC, Stage IIIA, NSCLC (non-small Cell Lung Cancer)
Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer
To investigate the efficacy and safety of neoadjuvant treatment with Tislelizumab combined with chemotherapy for initially unresectable N2/III non-small cell lung cancer.
- Trial name
- NCT06614231
- Testing
- Tislelizumab Combined With Chemotherapy
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)